(Q34658209)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Diana Giannarelli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Maddalena Barba

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Domenico Sergi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Marcello Maugeri

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

7

Laura Pizzuti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

4

Silverio Tomao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

9

Giancarlo Paoletti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

Franca Belli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

6

Maria Grazia Arena

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Luigi Di Lauro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Silvia Ileana Fattoruso

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

8 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

718-724

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Current questions for the treatment of advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Docetaxel: its role in current and future treatments for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Capecitabine in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-013-0321-3

Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer

21 January 2018

1 reference

12 December 2020

Geographic differences in approach to advanced gastric cancer: Is there a standard approach?

1 reference

12 December 2020

Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Grou

1 reference

12 December 2020

Identifying molecular drivers of gastric cancer through next-generation sequencing

1 reference

12 December 2020

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

1 reference

12 December 2020

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.

1 reference

12 December 2020

10.1007/S10120-013-0321-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 March 2020

1027111223

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24318671%20AND%20SRC:MED&resulttype=core&format=json